Addressing the Urgent Need for Patients Living with Rare Lung Disease

(BPT) - Although considered “rare,” idiopathic pulmonary fibrosis (IPF) impacts approximately three million people worldwide. With symptoms like breathlessness during activity, a dry and persistent cough, chest discomfort, weakness, or tiredness that can make everyday tasks exhausting, IPF is one of the most common forms of progressive interstitial lung diseases (ILD) – a category of over 200 lung disorders that can cause scarring of the lungs and may become life-threatening. The disease may also present a physical, mental, and emotional burden that can affect patients and their loved ones.

While current approved treatments for people living with IPF and other progressive fibrosing ILDs can help slow progression of the disease, new therapies are needed to help potentially stop damage that cannot be reversed.

New Research Underway

Fortunately, there is new research underway for an investigational treatment to see if it is safe and effective in adults with IPF and other progressive forms of ILDs. These trials are part of Boehringer Ingelheim’s global Phase III FIBRONEER™ program and were developed with feedback from healthcare providers, caregivers, and patients to best meet the needs of those living with the disease.

Boehringer Ingelheim is searching for adults with progressive fibrosing ILD to join this clinical research study. If you or your loved ones are interested, visit FIBRONEER-IPF.longboat.com and FIBRONEER-ILD.longboat.com for more details.